TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - REGENERON PHARMACEUTICALS Share Price

Certificat

DE000CL0LBU5

Delayed Deutsche Boerse AG 11:18:04 21/05/2024 BST
5.07 EUR -1.36% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - REGENERON PHARMACEUTICALS
Current month+17.89%
1 month+16.29%
Date Price Change
21/05/24 5.07 -1.36%
20/05/24 5.14 +1.18%
17/05/24 5.08 +2.01%
16/05/24 4.98 -1.58%
15/05/24 5.06 -1.94%

Delayed Quote Deutsche Boerse AG

Last update May 21, 2024 at 11:18 am

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
IssuerLogo Issuer Société Générale Société Générale
WKN CL0LBU
ISINDE000CL0LBU5
Date issued 06/11/2019
Strike 432.7 $
Maturity Unlimited
Parity 100 : 1
Emission price 0.19
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.34
Lowest since issue 0.096
Spread 0.14
Spread %2.69%

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
987.3 USD
Average target price
1,042 USD
Spread / Average Target
+5.54%
Consensus